Compare Biogen Inc (BIIB) vs Tidewater Inc (TDW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Tidewater Inc — how do they compare? Biogen Inc trades at $204.1 (market cap $30.13B), while Tidewater Inc trades at $91.74 (market cap $4.54B). The key difference: Biogen Inc is far larger — about 6.6× Tidewater Inc's market cap, and Tidewater Inc is trading nearer its 52-week high, Biogen Inc nearer its low. Which is the better fit depends on your goals.
| BIIB | TDW | |
|---|---|---|
Market Cap | $30.13B | $4.54B |
Sector | Health | Utilities |
52-Week High | $216.63 | $91.20 |
52-Week Low | $128.93 | $47.29 |
Enterprise Value | $37.20B | $4.58B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $208.85, up 0.83% with bullish technical signals and strong institutional support. The company has delivered three consecutive earnings beats, with Q2 2026 EPS of $3.60 exceeding estimates by 22%. Recent acquisition of RayThera and raised 2026 guidance demonstrate strategic growth initiatives. Valuation metrics show a P/E of 36.21 and P/S of 3.01, while maintaining solid profitability with 73.99% gross margins.
Biogen presents a compelling investment case with strong earnings momentum and strategic acquisitions driving growth. However, investors face risks from declining legacy MS drug sales and net income margin compression from 16.86% in 2024 to 8.32% projected for 2026. The stock offers 12% upside to consensus price target of $234.47, supported by 62.5% analyst buy ratings.
Tidewater (TDW) trades at $91.61, up 2.21% with strong technical momentum and bullish moving average signals. The company reported Q2 2026 earnings of $0.43 per share, beating estimates, with revenue of $342.3 million. Despite recent earnings misses, operational cash flow remains robust at $379 million for 2025, though 2026 projections show declining revenue and margins. Analyst sentiment is mixed with 26.9% buy ratings amid elevated RSI levels suggesting potential overbought conditions.
The stock faces headwinds from declining profitability trends and earnings volatility, but strong institutional ownership and positive technical indicators support near-term upside. Key risks include execution challenges and macroeconomic pressures on the offshore services sector. Investors should weigh solid cash generation against margin compression for balanced positioning.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Tidewater Inc
Tidewater is the leading global provider of offshore support vessels (OSVs) to the energy industry. With the world's largest fleet of platform supply vessels (PSVs) and anchor handling tugs (AHTS), it provides critical logistics and marine support for offshore oil, gas, and renewable energy projects. Following a period of massive strategic consolidation, Tidewater is now focused on maximizing day rates and free cash flow in a supply-constrained market, positioning itself as a primary beneficiary of the multi-year offshore upcycle.
Read more on TDW →
